TIM2 gene deletion results in susceptibility to cisplatin-induced kidney toxicity

Aparna Krishnamoorthy1, Matthew E Clement, Eileen O'Leary

  • 1Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Insights

T-cell Immunoglobulin and Mucin domain 2 (TIM2) deficiency exacerbates cisplatin-induced kidney injury. TIM2-deficient mice exhibit increased mortality, inflammation, and apoptosis, suggesting TIM2 plays a protective role in nephrotoxicity.

Area of Science:

  • Immunology
  • Nephrology
  • Toxicology

Background:

  • T-cell Immunoglobulin and Mucin domain 2 (TIM2) is a cell surface molecule found on kidney, liver, and T cells.
  • Previous research indicates TIM2-deficient mice are more susceptible to Th2-mediated airway inflammation.

Purpose of the Study:

  • To investigate the role of TIM2 in cisplatin-induced kidney toxicity.
  • To determine the phenotypic response of TIM2-deficient mice to nephrotoxic insult.

Main Methods:

  • Lethality study comparing wild-type (TIM2(+/+)) and TIM2-deficient (TIM2(-/-)) mice treated with cisplatin.
  • Assessment of kidney injury markers (blood urea nitrogen, serum creatinine) and histological analysis (H&E staining).
  • Quantification of Th1/Th2 cytokine expression, and analysis of apoptosis-related proteins (caspase-3, p53).

Main Results:

  • TIM2(-/-) mice exhibited significantly higher mortality (80%) compared to TIM2(+/+) mice (30%) after cisplatin administration.
  • Elevated kidney injury markers and proximal tubular damage were observed in TIM2(-/-) mice.
  • Increased expression of pro-inflammatory Th2 cytokines and pro-apoptotic markers (caspase-3, p53) was noted in TIM2(-/-) mice.

Conclusions:

  • TIM2 deficiency leads to increased susceptibility to cisplatin-induced nephrotoxicity.
  • The findings suggest a protective role for TIM2 in mitigating kidney damage and mortality from cisplatin exposure.

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...